William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiation
William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating.
William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating.